In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the in vitro diagnostic (ivd) in cardiology and neurology market?
The market size for in-vitro diagnostic (IVD) in the field of Cardiology and Neurology has experienced substantial growth in the past few years. An increase from $15.84 billion in 2024 to $17.27 billion in 2025 is expected, indicating a compound annual growth rate (CAGR) of 9.0%. The upward trend in the past can be linked to several factors including an increase in age-related cardiovascular and neurological conditions, a rise in the elderly population, an enhanced focus on preventative healthcare and early disease detection. Other contributing factors are the escalating burden of cardiovascular diseases (CVDs) and neurological conditions like stroke and Alzheimer’s disease, the growth in healthcare infrastructure investments, and an increase in the supportive regulatory frameworks that oversee the approval and reimbursement of diagnostic tests.
What will be the in vitro diagnostic (ivd) in cardiology and neurology market size in the future?
The market for in vitro diagnostic (IVD) specific to cardiology and neurology is forecasted to witness significant growth in the upcoming years, with an anticipated value of $24.07 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.7%. This surge during the forecast period is attributed to multiple factors including the evolving trend towards personalized medicine within cardiology and neurology, an escalating demand for swift and on-site diagnostic solutions in these spheres, the broadening scope of telemedicine and remote consultation services, and a rise in research initiatives. Major trends that will shape the forecast period include the emergence of liquid biopsy technologies, progress in nanotechnology, the utilization of remote monitoring devices, such as implantable cardiac monitors and brain-computer interfaces, application of multiplex biomarker panels, breakthroughs in medical imaging modalities, such as MRI, CT, and PET scans, and the development of companion diagnostics for cardiovascular and neurological drugs.
Get your in vitro diagnostic (ivd) in cardiology and neurology market report here!
What main drivers are fueling expansion in the in vitro diagnostic (ivd) in cardiology and neurology market?
The surge in personalized medicine is predicted to catalyze the growth of the in vitro diagnostic (IVD) market in cardiology and neurology sectors. Personalized medicine entails a healthcare approach guided by the unique attributes of each patient, insofar as making health decisions, executing practices, conducting interventions, and adopting treatments. The expansion of personalized medicine can be attributed to leaps in genomics, deeper understanding of disease processes, patient interest in customized treatments, and regulatory backing, among other elements. In vitro diagnostic (IVD) testing for cardiology and neurology aids personalized medicine by offering vital insight into a patient’s genetic composition and condition status, steering personalized treatment methods for better effectiveness and minimal risks. For instance, as indicated by the Personalized Medicine Coalition, a professional membership organization based in the US, in 2022, the sanctioning of 12 new personalized medicines accounted for about 34% of all freshly approved treatments, marking a significant jump from earlier years. Consequently, the proliferating number of personalized medicines is propelling the growth of the in vitro diagnostic (IVD) in cardiology and neurology market.
What key areas define the segmentation of the global in vitro diagnostic (ivd) in cardiology and neurology market?
The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Other End-Users
Subsegments:
1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices
2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables
3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp
Who are the dominant players expanding their reach in the in vitro diagnostic (ivd) in cardiology and neurology market?
Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience
What are the key trends shaping the future of the in vitro diagnostic (ivd) in cardiology and neurology market?
Leading firms in the cardiology and neurology in vitro diagnostic (IVD) market are leveraging artificial intelligence (AI) to develop integrated epigenetic engines for early disease detection and risk evaluation. These engines use machine learning models and sophisticated biomarker analysis techniques to increase the precision and sensitivity in diagnosing and monitoring heart-related diseases, thus addressing critical factors in disease progression. For example, Cardio Diagnostics Holdings Inc., a biotechnology firm based in the US, introduced an AI-powered blood test named PrecisionCHD in February 2023, designed specifically for the early detection of coronary heart disease (CHD). This test utilizes the company’s advanced epigenetic-genetic engine to assess CHD risk and aims at preventing and diagnosing the most prevalent form of heart disease. It merges epigenetic and genetic biomarkers with machine-learning algorithms, achieving over 75% sensitivity for both genders. The test connects a patient’s biomarker profile with changeable risk factors that contribute mainly to CHD, such as smoking, diabetes, hypertension and high cholesterol. PrecisionCHD serves as a non-invasive substitute to exercise stress tests or angiograms, allowing blood samples to be collected either at a medical office or at home.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829
Which regions are emerging as leaders in the in vitro diagnostic (ivd) in cardiology and neurology market?
North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Medical Image Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/medical-image-management-global-market-report
Image Guided Surgery Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/image-guided-surgery-devices-global-market-report
Artificial Intelligence (AI) Image Recognition Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
